Sukhwinder Singh Rai - 05 Jan 2023 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Reporting relationship: Director
Issuer ticker: SKYE
Reported as of: 05 Jan 2023
Net transaction value: +$4,250
SEC form: 4
Accepted by SEC: 09 Jan 2023, 09:30:23 UTC
Prior SEC filing: 15 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Kaitlyn Arsenault, as Attorney-in-Fact

Key filing fact

Sukhwinder Singh Rai filed Form 4 for Skye Bioscience, Inc. (SKYE) on 09 Jan 2023.

Key facts

This page summarizes Sukhwinder Singh Rai's Form 4 filing for Skye Bioscience, Inc. (SKYE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jan 2023, 09:30.

Change

Previous filing in this sequence was filed on 15 Nov 2022.
Current net transaction value: +$4,250.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SKYE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $4,250
Shares: +250,000
Change %
Price: $0.0170
Shares after: 250,000
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $0.0170
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 and the options will vest in equal monthly installments over the one year period beginning November 10, 2022.